AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
The study evaluated the safety and efficacy of C-CAR039, a novel anti-CD19/CD20 bi-specific CAR-T therapy. The dual-targeting approach to both CD20 and CD19 antigens aims to enhance therapeutic efficacy and reduce the likelihood of antigen escape, a common mechanism of resistance in B-cell malignancies.
Key Findings:
The overall response rate (ORR) and complete response (CR) rate were 91.5% and 85.1%, respectively for all patients
Among the 43 LBCL pts, ORR and CR were 90.7% and 86.0%, respectively
With a median follow-up of 45.5 months (range, 3.1–62.8), the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached
KM estimates of 48-m PFS rate are 52.5% for all patients and 53.4% for LBCL patients, respectively
KM estimates of 48-m OS rate are 65.4% for all patients and 66.7% for LBCL patients, respectively
Safety Highlights:
CRS of any grade: 93.8% | Grade ≥3: 2.1%
ICANS of any grade: 6.3% | No severe cases (Grade ≥3) reported
No new safety signals were observed with longer follow-up
C-CAR039 has continued to show an excellent safety profile and deep and durable responses in R/R B-NHL patients, especially in those with R/R LBCL. These results continue to provide strong support for the curative potential of C-CAR039 as a next-generation therapy for R/R B-NHL. Late-stage clinical development is ongoing.
"The long-term clinical outcomes data for C-CAR039 are highly encouraging, demonstrating sustained responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma," said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. "These results underscore our commitment and corporate goal to develop transformative therapies that address significant unmet medical needs in cancer."
Dr. Yihong Yao, Chief Scientific Officer of AbelZeta, commented, "The strong clinical results of C-CAR039 demonstrate the added value of targeting CD20 in addition to CD19 in aggressive B-NHL. By addressing the limitations of single-antigen therapies - such as CD19 antigen escape - C-CAR039 enables deeper tissue penetration and more complete B-cell depletion. The durable responses observed support the continued advancement of C-CAR039 as a promising new treatment for patients with aggressive B-cell malignancies."
For more information on the study and access to the poster presentation, please visit the EHA Library poster here.
AbelZeta previously presented 30-month Phase 1 clinical trial results at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, through oral presentation #1025, as well as at EHA 2024, through poster presentation #P1475. The data with 30 months follow up was published in Blood 2025 Apr 3;145(14):1526-1535.
AbelZeta Inc. (formerly known as Cellular Biomedicine Group, Inc.), entered into a worldwide collaboration and licensing agreement with Johnson & Johnson* in 2023 to develop and commercialize next-generation CAR-T cell therapies (excluding Greater China). The Phase 1 study for C-CAR039 was conducted by AbelZeta in China for the treatment of patients with B-cell non-Hodgkin lymphoma. Johnson & Johnson is evaluating the safety and efficacy of this asset (known as JNJ-90014496 outside of Greater China) through a separate study involving a global patient population. Phase 1b data for JNJ-90014496 were presented at EHA 2025 on Friday, June 13, informing the recommended Phase 2 dose and an initial assessment of safety, efficacy and pharmacokinetics in R/R LBCL patients. For more information, please visit Johnson and Johnson website: https://www.jnj.com/media-center/press-releases/johnson-johnsons-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-large-b-cell-lymphoma.
*The legal entity to the worldwide collaboration and license agreement is Janssen Biotech, Inc., a Johnson & Johnson company.
About AbelZeta Pharma, Inc.AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T therapies.
Forward-Looking StatementsStatements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
Company Contact:Sarah KellyDirector of CommunicationsAbelZeta Pharma, Inc.+1 (240) 552 5870sarah.kelly@abelzeta.comwww.abelzeta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-promising-long-term-outcomes-for-c-car039-a-novel-cd19cd20-bi-specific-car-t-therapy-in-patients-with-rr-b-nhl-at-eha-2025-302482119.html
SOURCE AbelZeta Pharma, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
Yahoo
an hour ago
- Yahoo
6 Biggest Money Mistakes When Buying a Car, According To ‘The Car Mom' and Rachel Cruze
Buying a car, whether it's a first set of wheels or the latest in a long line of vehicles, can feel like navigating a financial minefield. In a recent YouTube video, personal finance expert Rachel Cruze sat down with Kelly Stumpe, better known as 'The Car Mom,' to discuss some major mistakes people make when they're buying a car. Read More: Learn More: Recognizing these six mistakes upfront can help make car buying smarter and less costly. Test Driving Too Soon One of the first red flags is walking into a dealership before being ready to buy. According to Stumpe, buyers often go in with no intention of purchasing and walk out with a new car because they got swept up in the sales experience. Her advice is don't bring a trade-in, don't bring a partner, and don't test drive until the budget and plan are locked in. People need to have that 'Walk away, I need to think about it' feeling, she explained. Car dealerships can often instill a sense of urgency to try to get people to buy, but thinking about the purchase ahead of time is beneficial. 'Remember that you are the one with the final say, always. If you're feeling steamrolled, don't be afraid to walk away,' Carol Pope, a staff writer and car insurance agent, told LendingTree. Be Aware: Letting Emotions Drive the Decision Cruze and Stumpe also warned against letting emotions override logic. A high monthly payment might feel justifiable at first when the car is new and exciting. But several years down the line, when the car is scratched, stained and no longer fun to drive, that same car payment can start to sting. Failing To Forecast Ownership Needs A car that works today may not work two or three years from now. Stumpe told buyers — especially parents — to think ahead. Family size, lifestyle and cargo space needs often change before the loan is even halfway repaid. Buyers who ignore that risk may end up in a vehicle that no longer fits and a loan they can't easily escape. Letting the Dealership Set the Budget In another YouTube video, Stumpe shared how often buyers let the dealership define what's affordable. She recommended flipping the process: decide on a payment first, then use a calculator to work backward and determine the actual vehicle price. When setting your budget, U.S. News & World Report suggested finding a car where your monthly payment won't be more than 10% of your take-home pay. Skipping Salesperson Research Stumpe also recommended buyers research the salesperson, not just the dealership. Instead of leaving it to chance, finding highly reviewed individuals in advance can make a big difference in avoiding pressure, upsells and financial missteps. For women especially, choosing who to work with can makes a big difference in feeling confident and respected during the process. Not Having an Exit Plan Long-term financing has become the norm, with many buyers opting for 72- or even 84-month loans. But most people want a new car well before that term ends. Stumpe cautioned that without an exit strategy — whether it's passing the car to a partner, selling privately or trading in — buyers often end up owing more on their car than the car is actually worth. More From GOBankingRates 10 Cars That Outlast the Average Vehicle This article originally appeared on 6 Biggest Money Mistakes When Buying a Car, According To 'The Car Mom' and Rachel Cruze
Yahoo
an hour ago
- Yahoo
Trump Tariffs Leave Costly China Supply Question Unanswered
(Bloomberg) -- President Donald Trump's recent flurry of trade deals have given Asian exporters some clarity on tariffs, but missing are key details on how to avoid punitive rates that target China's supply chains. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy Trump unveiled tariffs of 20% for Vietnam and 19% for Indonesia and the Philippines, signaling those are the levels the US will likely settle on for most of Southeast Asia, a region that ships $352 billion worth of goods annually to the US. He's also threatened to rocket rates up to 40% for products deemed to be transshipped, or re-routed, through those countries — a move largely directed at curbing Chinese goods circumventing higher US tariffs. But still unclear to manufacturers is how the US will calculate and apply local-content requirements, key to how it will determine what constitutes transshipped goods. Southeast Asian nations are highly reliant on Chinese components and raw materials, and US firms that source from the region would bear the extra tariff damage. That's left companies, investors and economists facing several unanswered questions about Trump's tariffs that appear aimed at squeezing out Chinese content, according to Deborah Elms, head of trade policy at the Hinrich Foundation in Singapore. 'Is that raw materials? All raw materials? Above a certain percentage?' she said. 'How about parts? What about labor or services? What about investment?' In an agreement with Indonesia last week, the White House said the two countries would negotiate 'rules of origin' to ensure a third country wouldn't benefit. The deal with Vietnam earlier this month outlined a higher 40% tariff rate for transshipped goods. And Thai officials, who have yet to secure a deal, detailed that they likely need to boost local content in exports to the US. Missing Details The Trump administration isn't providing much clarity on the matter right now. US officials are still working out details with trading partners and looking at value-based local content requirements, to ensure exports are more than just assembled imported parts, according to a person familiar with the matter, who didn't want to be identified discussing private talks. A senior Trump administration official also said this week that details on the approach to transshipment are expected to be released before Aug. 1, the deadline for when higher US tariffs kick in. Some factories are already adjusting their supply chains to comply with rules that will require more locally-made components in production. Frank Deng, an executive at a Shanghai-based furniture exporter with operations in Vietnam — and which gets about 80% of business from the US — said in an interview his firm is making adjustments as authorities appear to be more strictly enforcing country-of-origin rules. Vietnam has always had specific local content requirements for manufacturers, Deng added, including that a maximum of 30% of the volume of raw materials originates from China, and the value after production in Vietnam must be 40% higher than the imported raw materials. 'We've been struggling to meet all the standards so that we can still stay in the game,' Deng said. 'But I guess that's the only way to survive now.' For most of Southeast Asia, reducing the amount of Chinese-made components in manufacturing will require a complete overhaul of their supply chains. Estimates from Eurasia Group show that Chinese components make up about 60% to 70% of exports from Southeast Asia — primarily industrial inputs that go into manufacturing assembly. About 15% of the region's exports now head to the US, up about four percentage points from 2018. Local Content The US has become increasingly vigilant about China's ability to bypass US trade tariffs and other restrictions through third countries since Trump's first trade war in 2017. Thailand signaled its frustration over the lack of clarity for how much local content is needed in goods exported to the US to avert transshipment rates, but noted it will likely be much higher than a traditional measure of 40%. 'From what we've heard, the required percentage could be significantly higher, perhaps 60%, 70%, or even 80%,' Deputy Prime Minister Pichai Chunhavajira said July 14. 'Emerging countries or new production bases are clearly at a disadvantage,' he said, as their manufacturing capabilities are still at an early stage and must rely on other countries for raw goods. Vietnam, Thailand and Malaysia have all taken steps this year to address Trump's concerns, increasing scrutiny of trade that passes through their ports including new rule-of-origin policies that centralize processing and imposing harsh penalties on transshippers. Developing nations may still struggle to enforce Trump's rules or comply with the rules if it means going up against China, their largest trading partner and geopolitical partner. 'The reality is it's not enforceable at all,' said Dan Wang, China director at Eurasia Group. 'Chinese companies have all kinds of ways to get around it and those other countries have no incentive to enforce those measures, or capacity to collect the data and determine local content.' --With assistance from Patpicha Tanakasempipat, Skylar Woodhouse and Nguyen Dieu Tu Uyen. Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P.
